Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 25, 2007

Invitrogen and Greiner Bio-One Ally to Better HPV Test Reliability

  • Invitrogen will help Greiner Bio-One improve the reliability of its HPV DNA test PapilloCheck® and DNA array CytoCheck® products. To avoid false-positives for PCR-based methods, Greiner Bio-One is incorporating into two of its DNA arrays a procedure patented by Invitrogen for preventing PCR carryover contamination.

    The license agreement covers the rights for the use of dUTP (deoxyuridine triphosphate) in PCR-based methods to prevent sample contamination by amplification products in aerosols.

    "The overall benefit of using the Invitrogen dUTP during the PCR is that false-positive results are reliably prevented at the beginning of the procedure, while the genuine sample DNA remains intact," explains Heinz Schmid, Greiner Bio-One managing director.

    During the PCR, dUTP is used instead of dTTP (deoxythymidine triphosphate). Any potential contaminating PCR-products can then be selectively degraded before starting a new reaction by the addition of the enzyme Uracil-DNA-glycosylase.

    Greiner Bio-One states that it will deliver the product kits for PapilloCheck with dUTP in the MasterMix beginning in June and CytoCheck including dUTP will be available this fall.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »